评估布地奈德直肠泡沫在 5 至 17 岁活动性轻至中度远端溃疡性结肠炎儿科患者中的安全性、有效性和药代动力学的剂量范围研究
一项随机、双盲、安慰剂对照、多中心、剂量范围研究,旨在评估布地奈德直肠泡沫 BID 2 周,随后 QD 4 周,在 5 至 17 岁儿童患者中的安全性、有效性和药代动力学活动性、轻度至中度远端溃疡性结肠炎
The primary objective of this study is to evaluate the efficacy (as measured by induction of remission) of two dose levels (low and high) per age group (5 to <12 and 12 to ≤17 years) of budesonide rectal foam as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in pediatric subjects with active, mild to moderate distal ulcerative colitis (UC).
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 第四阶段
联系人和位置
学习联系方式
学习联系方式
- 姓名:Varsha Bhatt
- 电话号码:707-285-1528
- 邮箱:Varsha.Bhatt@bauschhealth.com
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male and Female (non-pregnant and non-lactating) 5 to ≤17 years of age at Screening.
- Established diagnosis of UC, based on clinical history, characteristic endoscopic findings, and histopathology results from biopsies.
- Disease limited to the distal colon and rectum, (disease involving only the first 15 centimeters or less proximal to the anal verge).
- Active, distal UC of mild or moderate severity, defined as a Modified Mayo Clinic Score (mMCS) between 4 and 8, inclusive, that includes an endoscopy subscore ≥ 2 and a rectal bleeding subscore ≥ 1.
- If on a background oral 5-ASA, the dose and formulation have remained unchanged for at least 6 weeks prior to Visit 2 (Run-In) and the subject is willing to remain on the same dosage form and regimen for the duration of the study.
Exclusion Criteria:
-
Current or prior diagnosis of Crohn's disease or indeterminate colitis.
-
Ulcerative colitis involving the proximal colon - i.e, the sigmoid, left, transverse, and/or ascending colon and cecum;
-
Severe UC, defined as an mMCS > 8.
-
Infectious colitis (based on positive microbiologic tests at Screening) or any recent history of infectious colitis (within 30 days of Screening).
-
Prior gastrointestinal surgery, except appendectomy or hernia (e.g., inguinal, umbilical).
NOTE: Prior cholecystectomy is not exclusionary if more than 1 year prior to Screening.
-
Evidence or history of toxic megacolon or bowel resection.
-
Active proctologic pathology such as hemorrhoids, fistulas and fissures or other historical anatomic problems which would impair rectal administration (e.g., cloaca, imperforate anus history)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:大剂量布地奈德直肠泡沫
|
Twice a day for 2 weeks, then once a day for 4 weeks |
|
实验性的:小剂量布地奈德直肠泡沫
|
Twice a day for 2 weeks, then once a day for 4 weeks |
|
安慰剂比较:匹配安慰剂直肠泡沫
|
Twice a day for 2 weeks, then once a day for 4 weeks |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with clinical remission
大体时间:Day 42
|
Clinical remission based on the modified Mayo Clinic Score, defined as an endoscopy score ≤ 1 (excluding friability), a rectal bleeding subscore of 0, and at least a 1-point decrease in stool frequency subscore from Baseline to achieve a stool frequency subscore ≤ 1. Each component is scored from 0 to 3, with total scores ranging from 0 to 9, with higher scores indicating more severe disease. |
Day 42
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants who achieve a rectal bleeding subscale score of 0 at the end of six weeks of treatment
大体时间:Day 42
|
Scored from 0 to 3, with higher scores indicating more severe disease. |
Day 42
|
|
Proportion of participants who achieve a stool frequency subscale score of 0 at the end of six weeks of treatment.
大体时间:Day 42
|
Scored from 0 to 3, with higher scores indicating more severe disease. |
Day 42
|
|
Proportion of subjects who achieve an endoscopy subscale score of 0 or 1 at the end of six weeks of treatment.
大体时间:Day 42
|
Scored from 0 to 3, with higher scores indicating more severe disease. |
Day 42
|
合作者和调查者
调查人员
调查人员
- 研究主任:Varsha Bhatt、Bausch Health Americas, Inc.
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.